QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019
Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation
QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019
Venlo, The Netherlands, October 07, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces preliminary sales results for the third quarter of 2019 fall short of expectations.
For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Total sales growth was about 6% CER excluding China sales. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER.
5912 PL Venlo
Frankfurt Stock Exchange, regulated market (Prime Standard)
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711 and +1 240 686 2222
07-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: QIAGEN N.V. Hulsterweg 82 5912 PL Venlo
Netherlands Phone: +31 7735566 - 00 Fax: +31 77 35566-58 E-mail: email@example.com Internet: www.qiagen.com ISIN: NL0012169213 WKN: A2DKCH Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX EQS News ID: 886525 End of Announcement DGAP News Service
886525 07-Oct-2019 CET/CEST